<DOC>
	<DOCNO>NCT01377233</DOCNO>
	<brief_summary>The main purpose study evaluate safety , tolerability , pharmacokinetics weekly dose zicronapine , compare daily dose zicronapine .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Once Weekly Zicronapine Patients With Schizophrenia</brief_title>
	<detailed_description>The study include 2 treatment period . The open-label run-in period begin patient enrolment continue 3 week , patient receive daily treatment zicronapine . The double-blind period begin patient randomization continue 5 week , patient assign one group receive daily treatment zicronapine 3 group receive weekly treatment zicronapine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) A score &lt; =4 ( moderately ill ) Clinical Global Impression Severity Illness ( CGIS ) scale A total score &gt; =60 Positive Negative Syndrome Scale ( PANSS ) A score &lt; =4 ( moderate ) PANSS item : P7 ( hostility ) AND G8 ( uncooperativeness ) Acute exacerbation require hospitalization within last 3 month OR require change antipsychotic medication within last 4 week Diagnosis history substance dependence substance abuse accord DSMIVTR within last 3 month Significant risk harm himself/herself others Positive serology hepatitis A , B , C , HIV Present condition might compromise liver function Medical neurological disorder treatment could interfere study treatment compliance Previous exposure zicronapine Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Zicronapine</keyword>
	<keyword>Lu 31-310</keyword>
</DOC>